本页面由Tiger Trade Technology Pte. Ltd.提供服务

Inozyme Pharma

4.00
0.0000
成交量:- -
成交额:583.41万
市值:2.60亿
市盈率:-2.38
高:4.00
开:4.00
低:4.00
收:4.00
52周最高:6.24
52周最低:0.7210
股本:6,491.57万
流通股本:3,014.82万
量比:- -
换手率:- -
股息:- -
股息率:- -
每股收益(TTM):-1.6822
每股收益(LYR):-1.6243
净资产收益率:-141.69%
总资产收益率:-48.45%
市净率:8.17
市盈率(LYR):-2.46

数据加载中...

2022/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/10

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/07

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/11/15

重要事件披露

8-K - Current report
2021/11/15

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/11/09

重要事件披露

8-K - Current report
2021/11/09

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/08/19

SEC问询函

CORRESP [Cover] - Correspondence
2021/08/11

重要事件披露

8-K - Current report
2021/08/11

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/07/30

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/06/24

重要事件披露

8-K - Current report
2021/05/12

重要事件披露

8-K - Current report
2021/05/12

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/05/10

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/05/07

重要事件披露

8-K - Current report
2021/04/21

重要事件披露

8-K - Current report
2021/03/30

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/03/25

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans